India revokes patent on Merck & Co asthma drug

MUMBAI Tue Dec 11, 2012 7:24pm IST

A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009. REUTERS/Jeff Zelevansky/Files

A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009.

Credit: Reuters/Jeff Zelevansky/Files

Related Topics

Stocks

   

MUMBAI (Reuters) - India has revoked a patent granted to an asthma drug made by Schering Corp, later bought by U.S.-based Merck & Co (MRK.N), citing lack of invention, after Indian drugmaker Cipla Ltd (CIPL.NS) challenged an earlier decision.

The move is the latest in a series of patent cancellations by India, where generic medicines account for more than 90 percent of drug sales by value and whose huge potential to western drugmakers is undermined by intellectual property issues.

Earlier this year, India revoked Pfizer Inc's (PFE.N) (PFIZ.NS) patent on cancer drug Sutent, while an Indian patents appeal board overturned Roche Holding AG's (ROG.VX) patent on hepatitis C drug Pegasys.

The aerosol suspension formulation of the asthma drug, which won an Indian patent last year, combines three molecules: mometasone furoate, formoterol and heptaflouropropane. It was not immediately clear if Merck markets this drug under a specific brand name in India.

T.V. Madhusudhan, India's assistant controller of patents and design, said the patent-holder did not show an "inventive step" for the drug, either on individual parameters or in its entirety.

The ruling was posted on Tuesday on the website of the Indian patents office.

A similar asthma treatment, Dulera, lost its Indian patent held by Novartis AG (NOVN.VX) in 2010.

Officials at Merck could not immediately be reached for comment by Reuters.

(Reporting by Kaustubh Kulkarni; Editing by Tony Munroe and David Holmes)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Fuelling Change

REUTERS SHOWCASE

Quarterly Results

Quarterly Results

HDFC Bank net profit up 20 percent, lags estimates.  Full Article 

China Economy

China Economy

China's growth slowest since global crisis, annual target at risk  Full Article 

Coal Reforms

Coal Reforms

Factbox - India pushes ahead with coal reforms  Full Article 

Apple Result

Apple Result

Apple's iPhone sales beat Street but iPad volumes slide  Full Article 

Airport Accident

Airport Accident

Total CEO de Margerie killed in Moscow plane accident - airport spokeswoman.  Full Article 

Nadella's Paycheck

Nadella's Paycheck

New Microsoft CEO Nadella's pay tops $80 mln with big stock awards.  Full Article 

Deregulation Impact

Deregulation Impact

Private fuel retailers to dip toe, not dive back, into India  Full Article 

JLR China

JLR China

JLR sees 20 percent growth in China sales this year - exec  Full Article 

An RBI First

An RBI First

RBI releases minutes of financial stability council's Aug meet  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage